<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/28/3302498/0/en/Press-Release-Sanofi-s-venglustat-accepted-for-priority-review-in-the-US-to-treat-type-3-Gaucher-disease.html">Press Release: Sanofi&#39;s venglustat accepted for priority review in the US to treat type 3 Gaucher disease</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/19/3297843/0/en/Sanofi-Information-concerning-the-total-number-of-voting-rights-and-shares-April-2026.html">Sanofi: Information concerning the total number of voting rights and shares - April 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l&#39;Autorité des Marchés Financiers (Regulation of the French stock market authority)
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/sanofi-says-rare-lung-disease-drug-outperforms-standard-care-trial-2026-05-18/">Sanofi says rare lung disease drug outperforms standard care in trial</a>
    </div>

      <div class="me-0 me-md-5">
        French drugmaker Sanofi said on Monday ‌a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296985/0/en/Press-Release-ATS-phase-2-data-demonstrate-the-superiority-of-efdoralprin-alfa-over-a-standard-of-care-augmentation-therapy-in-achieving-higher-fAAT-levels-in-AATD.html">Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD</a>
    </div>

      <div class="me-0 me-md-5">
        ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/05/13/3-reasons-not-to-buy-into-the-hantavirus-related-b/">3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally</a>
    </div>

      <div class="me-0 me-md-5">
        The hantavirus isn&#39;t as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/sanofi-asks-pull-diabetes-drug-out-fda-voucher-program-stat-news-reports-2026-05-06/">Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator&#39;s new fast-track review program, STAT ​News reported on Wednesday.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-302764446.html">Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1</a>
    </div>

      <div class="me-0 me-md-5">
        The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/29/3284073/0/en/Press-Release-Annual-General-Meeting-of-April-29-2026-Bel%C3%A9n-Garijo-appointed-as-Director-and-Chief-Executive-Officer-of-Sanofi.html">Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi</a>
    </div>

      <div class="me-0 me-md-5">
        Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi&#39;s Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Sanofi-Sponsored-ADR-US80105N1054/load_more?page=6">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>